[1] Schubert N, et al. Phosphorylated extracellular signal-regulated kinase (pERK) activation in T effector cells as a target engagement biomarker for the DGKζ inhibitor BAY2965501 in clinical trials. Cancer Research, 2023, 83(7_Supplement): 2116-2116.
[2] Rienk Offringa, et al. 926BAY 2965501: a highly selective DGK zeta inhibitor for cancer immunotherapy. Regular and Young Investigator Award Abstracts. Immune Cell Types and Biology.
[3] Schlicher L, et al. Small molecule inhibitors for cancer immunotherapy and associated biomarkers - the current status. Front Immunol. 2023 Oct 31;14:1297175. DOI:
10.3389/fimmu.2023.1297175